R&D Insight

Workshop on TB drugs: Lessons for the antibacterial community

Dear All: ​I listened with interest to the 19 July 2017 FDA Workshop entitled “Development of New Tuberculosis Treatment Regimens– Scientific and Clinical Trial Design Considerations.” Most of the materials from the meeting are available online (see link below my signature).  I was interested in this workshop both because I want to see new TB

Read More »

Ways to talk about AMR / Video chat with Maryn McKenna

Dear All, Explaining AMR to our colleagues is not easy! I wrote in a 30 Oct 2019 newsletter about what Wellcome Trust learned on this point when they interviewed 12,000 people in Germany, India, Japan, Kenya, the UK, the USA and Thailand — in brief, there are universal themes that improve the likelihood that your message will

Read More »

REVAMP, a pull incentive in the US: Time to make it happen!

Dear All: I previously wrote about the nascent REVAMP legislation that would create a Pull incentive in the US market. With everybody back from the July 4th holiday, the goal for this week is to get REVAMP into position to be offered as an amendment at the House Energy & Commerce Committee’s PAHPA mark-up (expected next week).

Read More »

Approaches to antifungal R&D: A lecture from ISHAM

Dear All: ISHAM 2018, the meeting of the International Society for Human and Animal Mycology, is now happening in Amsterdam. I was given an opportunity to talk today on antifungal R&D and I thought I would share the slides with the broader community. It was really interesting to think about the parallels between antibacterials and

Read More »

Heads-up on REVAMP, a credible Pull incentive for the US!

Dear All: Incredibly exciting news! Due to the bipartisan efforts of Representatives John Shimkus (R-IL) and Tony Cardenas (D-CA), the Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 is now being introduced. This is the Pull incentive that we’ve been looking for in the US! The very short summary is that REVAMP (a) creates a new “priority antimicrobial product” category, (b) grants

Read More »

G7 Health ministers 3-4 June communique / Implications for choosing wisely

Note: Newsletter now updated to include the communique from the G7 Finance Ministers! Dear All, The G7 met in Oxford this past week and we now have communiques released from by both the Health and Finance Ministers. Let’s look first at the two fascinating statements from the Health Ministers: A general communique that includes multiple

Read More »

Amended Indian PPL slide / SUPERBUGS Act / Novo REPAIR Global Call

Dear All, Three bits of news you can use… First, when I wrote yesterday about the new Indian Priority Pathogen List (PPL), I said that it was similar to the WHO PPL list except for the addition of Staphylococcus epidermidis (and speculated that this relates to the role of S. epidermidis in neonatal sepsis). Well, it

Read More »
Scroll to Top